- Trials with a EudraCT protocol (155)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
155 result(s) found for: Hypopharynx.
Displaying page 1 of 8.
EudraCT Number: 2008-001354-41 | Sponsor Protocol Number: UCLONCO08-001 | Start Date*: 2008-04-11 | ||||||||||||||||||||||||||
Sponsor Name:Cliniques Universitaires St Luc, Centre du Cancer | ||||||||||||||||||||||||||||
Full Title: Neoadjuvant cetuximab monotherapy followed by surgery in squamous cell carcinoma of head and neck: phase I/II study | ||||||||||||||||||||||||||||
Medical condition: patients with squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx newly diagnosed and eligible for surgery. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-006091-38 | Sponsor Protocol Number: DeLOSII | Start Date*: 2007-05-31 | ||||||||||||||||
Sponsor Name:Universität Leipzig | ||||||||||||||||||
Full Title: Randomisierte Phase II Screeningstudie zum Einsatz einer TP/TPF-Chemotherapie (Kurzinduktion) vor TP/TPF-Induktion, Radiotherapie mit und ohne Cetuximab in der Primärtherapie des nur durch Laryngek... | ||||||||||||||||||
Medical condition: by laryngectomy operable carcinoma of the larynx and the hypopharynx | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) AT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003484-23 | Sponsor Protocol Number: Paccis-RCT_2005 | Start Date*: 2010-04-14 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Universitätsklinikum Erlangen, Strahlenklinik insoweit handelnd für den Freistaat Bayern | |||||||||||||||||||||||||||||||||||||||||||
Full Title: Randomised phase-III-trial of simultaneous radiochemotherapy (RCT) of locally advanced head and neck cancer in the stages III and IV A-B: Comparing dose reduced RCT (63.6 Gy) with Paclitaxel/Cispla... | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Head and Neck cancer, Stage III-IV A-B | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-012225-12 | Sponsor Protocol Number: 64-Cu-ATSM-CC-02/2009 | Start Date*: 2009-09-15 | ||||||||||||||||||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | ||||||||||||||||||||||||||||
Full Title: Role of 64Cu-ATSM PET/CT for the localization of hypoxic areas in head and neck cancer | ||||||||||||||||||||||||||||
Medical condition: head and neck cancer. MEDRA code has not been found. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004603-35 | Sponsor Protocol Number: REACH | Start Date*: 2009-04-28 | |||||||||||||||||||||
Sponsor Name:University of Heidelberg | |||||||||||||||||||||||
Full Title: Radiotherapy (IMRT), Erbitux And Chemotherapy For Unresectable Carcinomas Of Head and Neck. REACH-Study | |||||||||||||||||||||||
Medical condition: Histologically confirmed locally advanced (stage III or IV), non-metastatic squamous cell carcinoma of oro-, hypopharynx or larynx (T2-4, NX, M0). | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-003833-24 | Sponsor Protocol Number: AGMT_HNO_PN | Start Date*: 2016-06-30 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:AGMT – Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Randomized phase III study: Supplemental parenteral nutrition for patients with locally advanced inoperable tumors of the head and neck, receiving definitive radiotherapy with Cetuximab or Cisplatin | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Locally advanced inoperable tumors of the head and neck under definitive radiotherapy with Cetuximab or Cisplatin | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: AT (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-003226-33 | Sponsor Protocol Number: 0480 | Start Date*: 2018-09-13 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Dean of the Medical Faculty of the Friedrich-Alexander University Erlangen-Nürnberg Prof. Dr. Markus Neurath | |||||||||||||||||||||||||||||||||||||||||||
Full Title: First-line treatment of locally advanced HNSCC with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+ T cell infiltration (CheckRad-CD8) | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Locally advanced head and neck squamous cell carcinoma (HNSCC) | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-001584-11 | Sponsor Protocol Number: 70-3103 | Start Date*: 2008-06-14 |
Sponsor Name:MedUni Innsbruck Klinik für Strahlentherapie | ||
Full Title: Hyperfraktioniert akzelerierte Strahlentherapie (HART) mit Mitomycin C / 5-Fluorouracil versus Cisplatin / 5-Fluorouracil bei lokal fortgeschrittenen Kopf-Hals-Tumoren | ||
Medical condition: lokal fortgeschrittene Kopf-Hals-Tumoren | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-001416-27 | Sponsor Protocol Number: MEC-2012-130 | Start Date*: 2012-11-15 |
Sponsor Name:Erasmus MC | ||
Full Title: Treatment of Cancer in the head and Neck: The Role of Hyperbaric Oxygen in Reducing Swallowing Problems | ||
Medical condition: Nasopharynx, Oropharynx, Oral Cavity, Hypopharynx, Larynx | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-003977-10 | Sponsor Protocol Number: HNBE-03-02 | Start Date*: 2004-11-12 |
Sponsor Name:Genetronics Biomedical Corporation | ||
Full Title: A Randomized Trial Comparing Preservation of Function Status After Either MedPulser Electroporation With Intratumoral Bleomycin Therapy of Surgery in Patients With Locally Recurrent or Second Pri... | ||
Medical condition: Patients with locally recurrent or second primary SCC of the base tongue, posterior lateral pharyngeal wall, hypopharynx and larynx. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LV (Completed) GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2009-016489-10 | Sponsor Protocol Number: TPF-C-HIT | Start Date*: 2010-08-23 |
Sponsor Name:University of Heidelberg | ||
Full Title: Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanc... | ||
Medical condition: The study is a phase II study of induction chemotherapy with docetaxel plus cisplatin and fluorouracil (TPF) followed by radioimmunotherapy with Cetuximab and intensity modulated radiotherapy (IMRT... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-005540-99 | Sponsor Protocol Number: AGMT_HNO2 | Start Date*: 2013-03-05 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:AGMT – Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH | ||||||||||||||||||||||||||||||||||||||
Full Title: Randomised Phase II Pilot Studiy: Induction Chemotherapy with Docetaxel, Cisplatin und Cetuximab versus Docetaxel, Cisplatin und 5 FU followed by Radiotherapy with Cetuximab for locally advanced o... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Locally advanced or not resectable Carcinoma of the Head and Neck | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: AT (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-004384-22 | Sponsor Protocol Number: 2007-23 | Start Date*: 2007-12-05 |
Sponsor Name:CENTRE ANTOINE LACASSAGNE | ||
Full Title: ETUDE DE PHASE II EVALUANT UNE RADIOTHERAPIE - CHIMIOTHERAPIE + CETUXIMAB CHEZ DES PATIENTS PORTEURS D’UN CARCINOME EPIDERMOÏDE DE LA CAVITE BUCCALE, DE L’OROPHARYNX, DE L’HYPOPHARYNX OU DU LARYNX ... | ||
Medical condition: Patients porteurs d’un carcinome épidermoïde de la cavité buccale, de l’oropharynx, de l’hypopharynx ou du larynx histologiquement prouvé et de mauvais pronostic après chirurgie complète | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-000133-31 | Sponsor Protocol Number: AGO/2017/001 | Start Date*: 2017-07-31 |
Sponsor Name:UZ Gent | ||
Full Title: Combined hypofractionated stereotactic body radiotherapy with immunomodulating systemic therapy for inoperable recurrent head and neck cancer: detection of the maximum tolerated dose. | ||
Medical condition: local, regional or combined locoregional recurrence of squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx in previously irradiated tissue, with former irradiation with cu... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-000392-14 | Sponsor Protocol Number: 1200.131 | Start Date*: 2011-07-27 | |||||||||||
Sponsor Name:Boehringer Ingelheim Limited | |||||||||||||
Full Title: LUX-Head & Neck 2 A randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemoradiotherapy in primary... | |||||||||||||
Medical condition: Loco-regionally advanced head and neck squamous cell carcinoma with no evidence of disease after chemo-radiotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Prematurely Ended) BE (Completed) FR (Prematurely Ended) NL (Prematurely Ended) DE (Completed) FI (Prematurely Ended) GR (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended) IT (Completed) CZ (Prematurely Ended) DK (Prematurely Ended) PT (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004052-11 | Sponsor Protocol Number: UC-HNG/1909 | Start Date*: 2020-07-08 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:UNICANCER | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A phase II trial assessing Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in a pre-operative setting for resectable and untreated head and neck squamous cell carcinoma | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Histologically or cytologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx, previously untreated, with indication of primary surgery. Patients with a di... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: FR (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-002169-11 | Sponsor Protocol Number: 2007-002-0302-ONC | Start Date*: 2008-07-10 |
Sponsor Name:Royal Wolverhampton Hospitals Trust | ||
Full Title: Cost Analysis Of Cetuximab (Erbitux) Plus Radiotherapy (ERT) Versus Concomitant Cisplatin Plus Radiotherapy (CRT) Within An NHS Oncology Unit (New Cross Hospital Wolverhampton): A Pilot Study | ||
Medical condition: Squamous Cell Carcinoma or the oroplharynx, Larynx or Hypopharynx suitable for radical primary treatment with chemoradiotherapy | ||
Disease: | ||
Population Age: | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-013402-14 | Sponsor Protocol Number: INTECEPTOR-TRIAL | Start Date*: 2009-09-17 | |||||||||||
Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST | |||||||||||||
Full Title: INduction chemoThERapy followed by CEtuximab Plus definiTive radiOtheRapy versus radiation plus cisplatin | |||||||||||||
Medical condition: locally advanced squamous cell carcinoma of the head and neck | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001812-80 | Sponsor Protocol Number: 11-12-23/03-intern-6470 | Start Date*: 2011-11-25 | |||||||||||
Sponsor Name:Maastro Clinic | |||||||||||||
Full Title: Non invasive imaging of [18F]HX4 with Positron-Emission-Tomography (PET) in Head and Neck Cancer. | |||||||||||||
Medical condition: Patients with histological or cytological confirmed squamous cell carcinomas of the oral cavity, oropharynx, hypopharynx, larynx, T2-T3-T4, any N, M0 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002168-14 | Sponsor Protocol Number: nano-MRI.H&N.1 | Start Date*: 2019-02-12 |
Sponsor Name:Radboudumc | ||
Full Title: Validation of USPIO-enhanced MRI for detection of lymph node metastases in head and neck carcinoma: a pilot study. | ||
Medical condition: Lymph node metastases in patients with squamous cell head and neck carcinoma. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
